Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ionis Pharmaceuticals
Biotech
Ionis bags $30M from Recordati for ex-US rare disease rights
Ionis has offloaded regional rights to a near-approval rare disease asset, pocketing $30 million upfront from Recordati for an ex-U.S. license.
Nick Paul Taylor
Jun 25, 2026 6:59am
Intellia touts ‘paradigm-shifting’ HAE data
Jun 15, 2026 10:37am
GSK hep B drug cures one-fifth of patients in ‘major step’
May 28, 2026 4:30am
The 'diabolical' molecule set to become biotech's next gold rush
Apr 9, 2026 8:00am
Ionis scraps Alzheimer's candidate for people with Down syndrome
Feb 20, 2026 1:50pm
GSK's 'functional cure' for hep B proves worth in ph. 3 trials
Jan 7, 2026 6:15am
